{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:05:03Z","timestamp":1789502703147,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103385"],"award-info":[{"award-number":["82103385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Q201802-039"],"award-info":[{"award-number":["Y-Q201802-039"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14206-9","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:56:21Z","timestamp":1749185781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuxi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"14206_CR1","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1245\/s10434-021-09927-7","volume":"28","author":"SP Dineen","year":"2021","unstructured":"Dineen SP, Pimiento JM. The landmark series: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) for treatment of gastric Cancer metastatic to peritoneum. Ann Surg Oncol. 2021;28:4130\u20137.","journal-title":"Ann Surg Oncol"},{"key":"14206_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","volume":"20","author":"DK Chia","year":"2020","unstructured":"Chia DK, So JB. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020;20:115.","journal-title":"J Gastric Cancer"},{"key":"14206_CR3","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"P-E Bonnot","year":"2019","unstructured":"Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder J-M, Abboud K, Marchal F, Quenet F. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol"},{"key":"14206_CR4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.21037\/jgo-2020-04","volume":"12","author":"A Brandl","year":"2021","unstructured":"Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021;12:S32.","journal-title":"J Gastrointest Oncol"},{"key":"14206_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","volume":"12","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K. Pharmacokinetic study of Paclitaxel in malignant Ascites from advanced gastric cancer patients. World J Gastroenterology: WJG. 2006;12:1412.","journal-title":"World J Gastroenterology: WJG"},{"key":"14206_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1023\/A:1011680507956","volume":"12","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T. Phase II trial of Paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against Paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133\u20137.","journal-title":"Ann Oncol"},{"key":"14206_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000138978","volume":"74","author":"H Narahara","year":"2008","unstructured":"Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Taguchi T. Phase II study of a combination of S-1 and Paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74:37\u201341.","journal-title":"Oncology"},{"key":"14206_CR8","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/sj.bjc.6603497","volume":"95","author":"E Mochiki","year":"2006","unstructured":"Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K. Phase I\/II study of S-1 combined with Paclitaxel in patients with unresectable and\/or recurrent advanced gastric cancer. Br J Cancer. 2006;95:1642\u20137.","journal-title":"Br J Cancer"},{"key":"14206_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K. Nab-paclitaxel versus solvent-based Paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277\u201387.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"14206_CR10","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","volume":"14","author":"S Kobold","year":"2009","unstructured":"Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF Inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant Ascites?? Oncologist. 2009;14:1242\u201351.","journal-title":"Oncologist"},{"key":"14206_CR11","first-page":"2631","volume":"53","author":"JA Nagy","year":"1993","unstructured":"Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant Ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 1993;53:2631\u201343.","journal-title":"Cancer Res"},{"key":"14206_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of Ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"14206_CR13","doi-asserted-by":"crossref","unstructured":"Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T. VEGF is a target molecule for peritoneal metastasis and malignant Ascites in gastric cancer: prognostic significance of VEGF in Ascites and efficacy of anti-VEGF monoclonal antibody, oncotargets and therapy. 2013;1445\u201351.","DOI":"10.2147\/OTT.S51916"},{"key":"14206_CR14","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1200\/JCO.2006.08.0887","volume":"24","author":"MAR Shah","year":"2006","unstructured":"Shah MAR, Ramesh K, Ilson DHL, Alissa DOR, D\u2019Adamo, Eileen AT, Tse, Robin LC, Schwartz, Marinela GKK, Schwartz. David P, multicenter phase II study of Irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201\u20136.","journal-title":"J Clin Oncol"},{"key":"14206_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448\u201354.","journal-title":"J Clin Oncol"},{"key":"14206_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"14206_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, Lee K-W, Omori T, Shitara K, Sakuramoto S. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"14206_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet (London England). 2021;398:27.","journal-title":"Lancet (London England)"},{"key":"14206_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10147-020-01810-x","volume":"26","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, Hyodo I. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to Ascites burden. Int J Clin Oncol. 2021;26:370\u20137.","journal-title":"Int J Clin Oncol"},{"key":"14206_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jjco\/hyi109","volume":"35","author":"N Oriuchi","year":"2005","unstructured":"Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, Sakamoto J. A new, accurate and conventional five-point method for quantitative evaluation of Ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35:386\u201390.","journal-title":"Jpn J Clin Oncol"},{"key":"14206_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"14206_CR22","doi-asserted-by":"publisher","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","volume":"21","author":"H Maeda","year":"2015","unstructured":"Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant Ascites secondary to gastric cancer. World J Gastroenterology: WJG. 2015;21:10936.","journal-title":"World J Gastroenterology: WJG"},{"key":"14206_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jjco\/hyt114","volume":"43","author":"K Shirao","year":"2013","unstructured":"Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in Far advanced gastric cancer with peritoneal metastasis (JCOG0106. Jpn J Clin Oncol. 2013;43:972\u201380.","journal-title":"Jpn J Clin Oncol"},{"key":"14206_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10120-015-0542-8","volume":"19","author":"T Nishina","year":"2016","unstructured":"Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of Paclitaxel in Far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer. 2016;19:902\u201310.","journal-title":"Gastric Cancer"},{"key":"14206_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K. Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus Paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer. 2020;23:677\u201388.","journal-title":"Gastric Cancer"},{"key":"14206_CR26","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K. Phase III trial comparing intraperitoneal and intravenous Paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"14206_CR27","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","volume":"29","author":"SH Kang","year":"2022","unstructured":"Kang SH, Min S-H, Kim JW, Lee E, Park SW, Lee S, Oh HJ, Park YS, Lee YJ, Kim J-W. Safety and efficacy of intraperitoneal Paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29:5084\u201391.","journal-title":"Ann Surg Oncol"},{"key":"14206_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/or.2014.3210","volume":"32","author":"J Kinoshita","year":"2014","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based Paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep. 2014;32:89\u201396.","journal-title":"Oncol Rep"},{"key":"14206_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2016.05.004","volume":"63","author":"K Jordan","year":"2016","unstructured":"Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, R\u00fcssel J, Atanackovic D. Intraperitoneal bevacizumab for control of malignant Ascites due to advanced-stage Gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase II study\u2013AIO SUP-0108. Eur J Cancer. 2016;63:127\u201334.","journal-title":"Eur J Cancer"},{"key":"14206_CR30","doi-asserted-by":"publisher","first-page":"116820","DOI":"10.1016\/j.biopha.2024.116820","volume":"176","author":"PC Rietveld","year":"2024","unstructured":"Rietveld PC, Guchelaar NA, van Eerden RA, de Boer NL, de Bruijn P, Sassen SD, Madsen EV, Koch BC, Verhoef C, Burger JW. Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomed Pharmacother. 2024;176:116820.","journal-title":"Biomed Pharmacother"},{"key":"14206_CR31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M. The trifunctional antibody catumaxomab for the treatment of malignant Ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127:2209\u201321.","journal-title":"Int J Cancer"},{"key":"14206_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"A Ayantunde","year":"2007","unstructured":"Ayantunde A, Parsons S. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945\u20139.","journal-title":"Ann Oncol"},{"key":"14206_CR33","doi-asserted-by":"publisher","first-page":"030006052098666","DOI":"10.1177\/0300060520986664","volume":"49","author":"F Kou","year":"2021","unstructured":"Kou F, Gong J, Li Y, Li J, Zhang X, Li J, Shen L. Phase I study of intraperitoneal bevacizumab for treating refractory malignant Ascites. J Int Med Res. 2021;49:0300060520986664.","journal-title":"J Int Med Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14206-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:56:23Z","timestamp":1749185783000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14206-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14206"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14206-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicalble.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1010"}}